WHO, WIPO, WTO Technical Workshop on Patentability Criteria

> October 2015 Dr. Peter Beyer



# Covering broad class of compounds (Markush claim)

"selection patent" for subgroup of compounds

Individual compound

Crystalline forms

Compositior

& dosage

Typical patent flow for pharmaceuticals (chemicals) WO2005003147A2: Modified fluorinated nucleoside analogues claimed through Markush structure


> <u>WO2008121634A2</u>: general structural formula (Markush) / phosphoramidate prodrugs of nucleoside derivatives

> > WO2011123645A2: seeks to protect all crystalline forms

Example sofosbuvir www.who.int/phi/implementa tion/ip\_trade/ip\_patent\_land scapes/en/ <u>WO2013040492A2</u>: combination of sofosbuvir/ ledipasvir

> WO2013082003 A1: composition & unit dosage form

#### Sofosbuvir: Expected expiry without patent term extension(s)



### **Incremental innovation vs life cycle management**

Incremental advances for public health can include:

- Combinations & new dosage forms with improved efficacy: co-formulation of antiretroviral drugs
- Formulations with better product characteristics: vaccines stored in fridge rather than freezer
- New routes of delivery: tablets or nasal spray vs injections
- Paediatric formulations: dispersible flavored tablet of artemether-lumefantrine



5



"...a key element of life cycle management strategies is to extent patent protection for as long as possible by filing secondary patents to keep generics off the market." (Burdon and Sloper 2003)

# Prilosec – Nexium (omeprazole/esomeprazole)

# Proton pump inhibitor that inhibits gastric acid secretion

"It has surprisingly been found that the magnesium salt of S-omeprazole occurs in a number of structurally different forms. It is an object of the present invention to provide a substantially pure magnesium salt of S-omeprazole trihydrate...." (US 6,369,085 B1)

#### **Nexium = single-isomer version of Prilosec**



### **Omeprazole vs. esomeprazole**

US Patent No.	Filing Date	Expiry	Description
US 4255431	Apr 5, 1979	2001	Original compound patent
US 6369085	May 5, 1998	2018	Novel form of S- omeprazole

**Marketing:** US\$500 mill/year following launch (New Yorker 2004) **Revenue 2006:** >US\$ 5 billion

Vernaz et al.: €5,2 mill 2000 - 2008 extra costs in Geneva Hospitals

PLOS Medicine June 2013 Vol 10:6 page 2-12

8 Public health, innovation and intellectual property



## Rituximab: subcutaneous vs. intravenous

Benefits: 5 minutes injection vs. several hours

- Patients' preferences (Pivot et al. 2013)
- Savings in healthcare professional time and costs (Rule et al 2014)
- Intravenous patent expires in 2013
- Subcutaneous patent expires in 2030

Is every switch from IV to subcutaneous inventive? Would companies do this step if they would not get a patent?



# Where to draw the line?


#### **Opposing trends:**

- Argentina, India and Philippines follow new approaches in the pharmaceutical area to limit secondary patents
  Brazil and South Africa consider similar rules
- US through trade agreements endeavours to expand patentability, eg secondary uses, methods of use and to prevent limitation of secondary patents



- Definition of patentability criteria can impact health budgets
- What is incremental innovation and what is "life cycle management"?
- Do all incremental improvements merit a 20 year patent?

Innung 2007 WHO - ICTSD - UNCTAD



#### ICTSD, UNCTAD, WHO, Guidelines for the examination of pharmaceutical patents: developing a public health perspective

http://www.who.int/phi/publications/category/en/

Dr Peter Beyer Senior Advisor World Health Organization beyerp@who.int Tel. +41-22-791 25 07

